## **Common Drug Review \***

**Submission Status** 

Product: Exjade Generic Name: deferasirox

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Submission Type: New

Date Submission Received: 2006-Oct-26

Date NOC Issued: Targeted CEDAC Meeting: 2007-Mar-21

**Priority Review Granted:** Denied

2006-Oct-18

Target	Actual	
Date**	CDR Date	Comments
2006-Nov 02	2006-Nov 02	Priority review requested. Priority review denied November 8, 2006. Submission placed in queue in accordance with CDR procedures. Review to be initiated pending availability of resources. Review initiated November 27, 2006.
2007-Jan-31	2007-Feb-05	Additional information requested December 4, 2006. Partial information received December 5, 2006. Additional information received December 6, 2006. Additional information requested January 5, 2007. Remaining information from December 4, 2006 request received January 8, 2007. Additional information received January 12, 2007. Additional information requested January 18, 2007. Additional information received January 24, 2007.
2007-Feb-09	2007-Feb-14	Due date for manufacturer's comments February 14, 2007.
2007-Feb-20	2007-Feb-23	Due date for reviewers' replies February 23, 2007.
2007-Mar-07	2007-Mar-07	
2007-Mar-21	2007-Mar-21	
2007-Mar-28	2007-Mar-28	
2007-Apr-12	2007-Apr-12	
2007-Apr-19	2007-Apr-19	Notice of Final Recommendation issued.
	2006-Nov 02  2007-Jan-31  2007-Feb-09  2007-Feb-20  2007-Mar-07  2007-Mar-21  2007-Mar-21	2006-Nov 02 2006-Nov 02  2007-Jan-31 2007-Feb-05  2007-Feb-09 2007-Feb-14  2007-Feb-20 2007-Feb-23  2007-Mar-07 2007-Mar-07  2007-Mar-21 2007-Mar-21  2007-Apr-12 2007-Apr-12

<sup>\*</sup> Refer to the Procedure for Common Drug Review on the Common Drug Review section of <a href="https://www.cadth.ca">www.cadth.ca</a> for more details.

\*\* The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule,

which is posted on <a href="https://www.cadth.ca">www.cadth.ca</a>.
\*\*\* The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.